Of particular note, the low-risk group showed a significant increase in CD8+ T cells and M1 macrophages, which have been shown to promote the infiltration of inflammatory cells in the tumour microenvironment (Chen et al., 2023), further demonstrating that patients in this group have a better prognosis through a stronger immune response. The gene discussed is CD8A; the disease is neoplasm.